Differences in the Psychopharmacological Trajectories of School-Age Children with Attention-Deficit/Hyperactivity Disorder with and without Intellectual Disability

Francisca Bastos Maia; Vânia Martins Miranda

doi:10.20344/amp.20712

Authors

Francisca Bastos Maia Childhood and Adolescence Mental Health and Psychiatry Department. Unidade Local de Saúde de Santo António. Porto. Portugal.
Vânia Martins Miranda Childhood and Adolescence Mental Health and Psychiatry Department. Unidade Local de Saúde de Santo António. Porto. Portugal.

DOI:

https://doi.org/10.20344/amp.20712

Keywords:

Intellectual Disability, Antipsychotic Agents, Attention Deficit Disorder with Hyperactivity, Child, Psychotropic Drugs

Abstract

Introduction: Attention-deficit/hyperactivity disorder (ADHD) affects 5% - 7% of school-aged children, while intellectual disability (IDD) affects approximately 1% of the general population. Diagnosing and treating ADHD in individuals with IDD is challenging, not only due to communication difficulties but also because of psychiatric comorbidities that may be present. These factors can result in underdiagnosis of ADHD and increased prescribing of other psychotropic medications. The aim of this study was to determine differences in psychopharmacological treatment (number of prescribed psychostimulants, inefficacy, adverse effects) and in the number of comorbidities and other prescribed psychotropic drugs between patients with ADHD, with and without ID.
Methods: In the study, 845 children were included, divided into two groups: 574 with ADHD without ID and 271 with ADHD with ID. Microsoft® Excel® was used to calculate the Student’s t-test, and statistical significance was assumed using the standard p-value of < 0.05.
Results: No significant differences were found in the average number of psychostimulants prescribed between groups (p = 0.57). Among those with ADHD without ID, 52.4% switched psychostimulants, while in the group with ADHD and ID, this change occurred in 56.1%. Statistically significant differences were found in the average number of other psychotropic medications prescribed per patient (p < 0.05) and in the number of antipsychotics prescribed (p < 0.05). Although our study showed more antipsychotic prescriptions for patients with ID compared to those without ID, some studies report similar use of antipsychotics between these groups. Additionally, the group with ID presented significantly more comorbidities than the group without ID (p < 0.05). These findings are aligned with the literature, which indicates a higher prevalence of psychiatric comorbidities in samples of patients with ID compared to those without ID (50% vs 18%).
Conclusion: Individuals with ID are diagnosed with more psychiatric comorbidities and are prescribed more psychotropic drugs. Additionally, more adverse effects and inefficacy with psychostimulants in ID populations require careful monitoring after initiation.

Downloads

References

Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and metaanalysis. Pediatrics. 2015;135:994-1001.

American Psychiatry Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Publishing; 2013.

National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. 2018. [cited 2024 Jul 03]. Available from: https://www.nice.org.uk/guidance/ng87/resources/ attention-deficit-hyperactivity-disorder-diagnosis-and-managementpdf- 1837699732933.

Winterstein AG, Soria-Saucedo R, Gerhard T, Correll CU, Olfson M. Differential risk of increasing psychotropic polypharmacy use in children diagnosed with ADHD as preschoolers. J Clin Psychiatry. 2017;78:744- 81.

Reale L, Bartoli B, Cartabia M, Zanetti M, Constantino MA, Canevini MP, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26:1443- 57.

Larsson I, Aili K, Lonn M, Svedberg P, Nygren JM, Ivarsson A, et al. Sleep interventions for children with attention deficit hyperactivity disorder (ADHD): a systematic literature review. Sleep Medicine. 2022;102:64- 75.

Efron D, Lycett K, Sciberras E. Use of sleep medication in children with ADHD. Sleep Med. 2014;15:472-5.

Becker SP. ADHD and sleep: recent advances and future directions. Curr Opin Psychol. 2020;34:50-6.

Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419-36.

Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res. 2003;47:51-8.

Moura O, Costa P, Simões MR. WISC-III cognitive profiles in children with ADHD: specific cognitive impairments and diagnostic utility. J Gen Psychol. 2019;146:258-82.

Miller J, Perera B, Shankar R. Clinical guidance on pharmacotherapy for the treatment of attention-deficit hyperactivity disorder (ADHD) for people with intellectual disability. Expert Opin Pharmacother. 2020;21:1897-913. 13. Cooper SA, Smiley E, Morrison J, Williamson A, Allan L. Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. Br J Psychiatry. 2007;190:27-35.

Turk J. Sleep disorders in children and adolescents with learning disabilities and their management. Adv Ment Health Learn Disabil. 2010;4:50-9.

Lihabi AA. A literature review of sleep problems and neurodevelopment disorders. Front Psychiatry. 2023;14:1122344.

Osunsanmi S, Turk J. Influence of age, gender, and living circumstances on patterns of attention-deficit/hyperactivity disorder medication use in children and adolescents with or without intellectual disabilities. J Child Adolesc Psychopharmacol. 2016;26:828-34.

Perera B, Chen J, Korb L, Borakati A, Courtenay K, Henley W, et al. Patterns of comorbidity and psychopharmacology in adults with intellectual disability and attention deficit hyperactivity disorder: an UK national cross-sectional audit. Expert Opin Pharmacother. 2021;22:1071-8.

Aman MG, Kern RA, Mcghee DE, Arnold LE. FenfluramiI and methylphenidate in children with mental retardation and ADHD: clinical and side effects. J Am Acad Child Adolesc Psychiatry. 1993;32:851-9.

Hande BL, Feldman H, Gosling A, Breaux AM, McAuliffe S. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry. 1991;30:241-5.

Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, et al. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry. 2012;54:527-35.

Tarrant N, Roy M, Deb S, Odedra S, Retzer A, Roy A. The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: a systematic review. Res Dev Disabil. 2018;83:217-32.

Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-7.

Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 4th ed. New York: Guilford Press; 2015.

Hesapcioglu ST, Ceylan MF, Kasak M, Yavas CP. Psychiatric comorbidities of mild intellectual disability in children and adolescents in a clinical setting. Int J Dev Disabil. 2019;67:151-7.

Dekker MC, Koot HM, van der Ende J, Verhulst FC. Emotional and behavioral problems in children and adolescents with and without intellectual disability. J Child Psychol Psychiatry. 2002;43:1087-97.

Emerson E, Hatton C. Mental health of children and adolescents with intellectual disabilities in Britain. Br J Psychiatry. 2007;191:493-9.